Journal article · 2026

A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide

Ann Marie Navar, Elina Mikhailova, Alberico Luigi Catapano, Puja Banka, Dirk Jacobus Blom, Alberto Cadena, Susan Kourpanidis, Norman E. Lepor, Kazuhisa Tsukamoto, Geraldine Mendizabal, Julio Nunez, Wenjuan Zhang and 3 more

New England Journal of Medicine, 394(6), 529–539 · Published 4 February 2026 · DOI 10.1056/nejmoa2511002

View at the publisherCite this paper

In brief

“A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide” is a 2026 journal article by Ann Marie Navar and 14 co-authors, published in New England Journal of Medicine. OpenAlex counts 77 citations as of 20 November 2026, which puts it in the top 1% of works published in 2026 by citations. The publisher's version is not open access, and OpenAlex records no free legal copy.

Citations
77
Most cited in
2026 (77)
Field-weighted impact
238.48
References
23
Authors
15

Abstract

BACKGROUND: Enlicitide decanoate, an oral proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor, was shown to reduce low-density lipoprotein (LDL) cholesterol levels in a phase 2 trial; longer-term data are needed. METHODS: In this multinational, double-blind, randomized, placebo-controlled trial, we enrolled adults with a history of a major atherosclerotic cardiovascular disease event with an LDL cholesterol… Read the full abstract at the publisher.

Excerpt. This paper is not open access.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Navar, A. M., Mikhailova, E., Catapano, A. L., Banka, P., Blom, D. J., Cadena, A., Kourpanidis, S., Lepor, N. E., Tsukamoto, K., Mendizabal, G., Nunez, J., Zhang, W., Zhu, P., Zhuo, M., & Ballantyne, C. M. (2026). A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide. New England Journal of Medicine, 394(6), 529–539. https://doi.org/10.1056/nejmoa2511002

MLA 9

Navar, Ann Marie, et al. “A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide.” New England Journal of Medicine, vol. 394, no. 6, 2026, pp. 529–539. https://doi.org/10.1056/nejmoa2511002.

Chicago

Navar, Ann Marie, Elina Mikhailova, Alberico Luigi Catapano, Puja Banka, Dirk Jacobus Blom, Alberto Cadena, Susan Kourpanidis, et al. 2026. “A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide.” New England Journal of Medicine 394 (6): 529–539. https://doi.org/10.1056/nejmoa2511002.

Harvard

Navar, A. M. et al. (2026) ‘A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide’, New England Journal of Medicine, 394(6), pp. 529–539. doi:10.1056/nejmoa2511002.

IEEE

A. M. Navar et al., “A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide,” New England Journal of Medicine, vol. 394, no. 6, pp. 529–539, 2026, doi: 10.1056/nejmoa2511002.

BibTeX

@article{navar2026placebo,
  title     = {{A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide}},
  author    = {Navar, Ann Marie and Mikhailova, Elina and Catapano, Alberico Luigi and Banka, Puja and Blom, Dirk Jacobus and Cadena, Alberto and Kourpanidis, Susan and Lepor, Norman E. and Tsukamoto, Kazuhisa and Mendizabal, Geraldine and Nunez, Julio and Zhang, Wenjuan and Zhu, Pengfei and Zhuo, Min and Ballantyne, Christie M.},
  journal   = {New England Journal of Medicine},
  year      = {2026},
  volume    = {394},
  number    = {6},
  pages     = {529--539},
  doi       = {10.1056/nejmoa2511002},
  url       = {https://doi.org/10.1056/nejmoa2511002}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health

  • PCSK9 inhibitors
  • LDL cholesterol lowering
  • atherosclerotic cardiovascular disease
  • hypercholesterolemia
  • non-HDL cholesterol
  • apolipoprotein B
  • lipoprotein(a)
  • cardiovascular risk reduction

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Navar, A. M., Mikhailova, E., Catapano, A. L., Banka, P., Blom, D. J., Cadena, A., Kourpanidis, S., Lepor, N. E., Tsukamoto, K., Mendizabal, G., Nunez, J., Zhang, W., Zhu, P., Zhuo, M., & Ballantyne, C. M. (2026). A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide. New England Journal of Medicine, 394(6), 529–539. https://doi.org/10.1056/nejmoa2511002

How many times has this paper been cited?

77 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.

Who wrote this paper?

Ann Marie Navar, Elina Mikhailova, Alberico Luigi Catapano, Puja Banka, Dirk Jacobus Blom, Alberto Cadena, Susan Kourpanidis, Norman E. Lepor, Kazuhisa Tsukamoto, Geraldine Mendizabal, Julio Nunez, Wenjuan Zhang and 3 more.

What is the DOI of this paper?

10.1056/nejmoa2511002, permanently at https://doi.org/10.1056/nejmoa2511002. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.